Clinical trials: Unknown Primary Cancer
Leukemia, Hematologic Malignancy
Solving Riddles Through Sequencing
During the last decades hematologists have excelled at improving and refining the classification, diagnosis, and thus ultimately the therapeutic decision-making process for their patients.
- Conditions
- Leukemia, Hematologic Malignancy, Rare Diseases, Refractory Leukemia
- Trial name
- SIRIUS (NCT05046444)
- Testing
- Next Generation Sequencing
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Munich Leukemia Laboratory
Advanced Unspecific Symptom, Cancer of Unknown Primary Site
Smartphone-Based Self-Registration of Health Data in Patients With Severe Unspecific Symptoms or Cancer of Unknown Primary
This study evaluates whether self-registration of health data through a smartphone application can benefit patients undergoing diagnostic evaluation for severe unspecific symptoms (AOS) or cancer of unknown primary (CUP) at the…
- Trial name
- AID-PM-001 (NCT07898280)
- Testing
- Smartphone app enabling self-registration of physical and mental health
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- University of Skövde
Melanoma, Myelodysplastic Syndrome
SCRI Tissue Testing Registry
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients…
- Conditions
- Melanoma, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
- Trial name
- NCT00965861
- Testing
- Tissue Registry Study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SCRI Development Innovations, LLC
Squamous Cell Carcinoma of the Oropharynx, Carcinomas of Unknown Primary Site
Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus
Based on the evidence summarized in the introduction, the clinician hypothesize that the detection of the presence and expression of HPV-DNA, certain miRNAs, and a certain mutational profile in the tissues and biological fluids…
- Conditions
- Squamous Cell Carcinoma of the Oropharynx, Carcinomas of Unknown Primary Site, High-risk Human Papillomavirus Infection, Liquid Biopsy
- Trial name
- NCT05918510
- Testing
- Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx
- Where
- Italy
- Volunteers
- 142 people
- Sponsor
- Regina Elena Cancer Institute
Carcinoma of Unknown Primary, Head and Neck Cancer
PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
RATIONALE: Imaging procedures, such as PET scan and CT scan, may help doctors predict a patient's response to treatment and plan the best treatment.
- Trial name
- NCT00388024
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Wake Forest University Health Sciences
Cancer, Breast Cancer
Genomic Investigation of Unusual Responders
Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic…
- Conditions
- Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- GENIUS (NCT03740503)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Carcinoma of Unknown Primary, Head and Neck Cancer
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003582
- Testing
- amifostine trihydrate, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Miami
Unknown Primary Tumors
A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)
Agnostos Trial is a multicentric phase 2 randomized trial with a 'pick-the-winner design' in chemonaive patients with cancer of unknown primary.
- Trial name
- AGNOSTOS (NCT02607202)
- Testing
- nab-paclitaxel, Carboplatin, Gemcitabine
- Where
- 10 sites in Italy
- Volunteers
- 57 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Bile Omics for Diagnosing Indeterminate Biliary Strictures
The diagnosis of malignant biliary strictures remains a challenging aspect of biliary endoscopy. Molecular biological testing techniques based on bile have been reported to improve detection rates.
- Conditions
- Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Strictures of Unknown Origin
- Trial name
- NCT07007832
- Testing
- Endoscopic retrograde cholangiopancreatography
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Colorectal Carcinoma, Health Status Unknown
Lay Health Worker Outreach in Increasing Colorectal Cancer Screening in Asian Americans
This randomized clinical trial studies how well a lay health worker outreach works in increasing colorectal cancer screening in Asian Americans.
- Conditions
- Colorectal Carcinoma, Health Status Unknown, Healthy Subject
- Trial name
- NCT03115372
- Testing
- Educational Intervention, Informational Intervention, Survey Administration
- Where
- 4 sites in United States
- Volunteers
- 982 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Cancer of Unknown Primary Site, Unknown Primary Cancer
Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary
Adult patients suspected of Squamous Cell Carcinoma of Unknown Primary (SCCUP) will be prospectively enrolled at a tertiary head \& neck cancer center at Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Conditions
- Cancer of Unknown Primary Site, Unknown Primary Cancer, Unknown Primary, Squamous Cell Carcinoma
- Trial name
- OP-CUP (NCT05841966)
- Testing
- Transoral Ultrasound
- Where
- 2 sites in Denmark
- Volunteers
- 30 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Breast Cancer Diagnosis, Breast Cancer Prevention
Contrast Enhanced Mammography in the Evaluation of Cancer of Unknown Primary Syndrome
This study aims to evaluate the role of Contrast-Enhanced Mammography (CEM) in identifying the primary tumor site in patients presenting with Cancer of Unknown Primary (CUP) syndrome.
- Trial name
- CEM_CUP_syndr (NCT06843096)
- Testing
- Contrast-Enhanced Mammography (CEM)
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- Graziella di Grezia
Carcinoma of Unknown Primary, Colorectal Cancer
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Carcinoma of Unknown Primary, Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00004005
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Study of Mucosal Sparing Adjuvant Radiotherapy After Surgical Exploration in HPV+ Head and Neck Cancer of Unknown Primaries
This clinical trial evaluates the clinical outcome of mucosal sparing adjuvant radiotherapy after surgical exploration in HPV+ head and neck cancer of unknown primaries.
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary
- Trial name
- NCT04489212
- Testing
- Medical Chart Review, Patient Observation, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Neoplasms, Unknown Primary, CUP
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make treatment decisions using targeted…
- Conditions
- Neoplasms, Unknown Primary, CUP, Metastatic Disease, Poorly Differentiated Adenocarcinoma
- Trial name
- NCT02628379
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Foundation Medicine
Metastasis Cervical Lymph Nodes of Unknown Primary Carcinoma
The Final Diagnosis and Treatment Result of Metastatic Cervical Carcinoma of Unknown Primary
Investigate the final diagnosis and treatment result of metastatic cervical carcinoma of unknown primary
- Trial name
- NCT00302588
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
This phase II trial compares the effect of adding olanzapine to standard of care symptom management for nausea to standard of care alone in managing an abnormal loss of the appetite for food (anorexia) in patients treated with…
- Conditions
- Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma, Neck Squamous Cell Carcinoma of Unknown Primary
- Trial name
- NCT06995508
- Testing
- Best Practice, Olanzapine, Questionnaire Administration
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Roswell Park Cancer Institute
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Pancreas Neoplasms, Lymphatic Metastasis
Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying Lesions
The purpose of this study is to compare the diagnosis accuracy of modified wet suction technique and 5ml dry suction technique on solid occupying lesions.
- Conditions
- Pancreas Neoplasms, Lymphatic Metastasis, Neoplasm Metastases, Unknown Primary Neoplasm Metastasis
- Trial name
- NCT02789371
- Testing
- the first pass is made with 5ml suction technique, the first pass is made with modified wet suction technique
- Where
- China
- Volunteers
- 296 people
- Sponsor
- Bin Cheng
Carcinoma of Unknown Primary
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
This study is for patients with a type of cancer called carcinoma of unknown primary site (CUP), meaning that the site of the body where the tumor has originated is not clear.
- Trial name
- NCT00148135
- Testing
- Carboplatin, Gemcitabine, Capecitabine
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center